Exosomes from Modified MSCs for Ovarian Insufficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for addressing premature ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS), particularly in preventing infertility and metabolic abnormalities associated with these conditions.
Innovation Solution
Administration of mesenchymal stem cells (MSCs) or their secretome, which overexpress miR144, BMP-2, TGFβ1, and IL-10, or exosomes produced by these MSCs, to treat or prevent POI and PCOS, promoting ovarian health and fertility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for POI and PCOS, then current standard care is provided, but infertility and metabolic abnormalities are not effectively prevented or treated
Solution Approach 1:
The patent modifies the functional parameters of mesenchymal stem cells by inducing overexpression of specific molecules (miR144, BMP-2, TGFβ1, IL-10) through genetic modification. This parameter change enhances the therapeutic efficacy of MSCs in treating POI and PCOS, leading to improved fertility outcomes and metabolic parameters compared to conventional untreated MSCs
Solution Approach 2:
The patent uses exosomes as cellular copies or messengers that carry therapeutic molecules from modified MSCs to target tissues. These exosomes replicate the therapeutic function without requiring the full complex MSC structure, enabling treatment through a simplified delivery vehicle that maintains therapeutic effectiveness
2Reliability
If mesenchymal stem cells are administered to treat POI and PCOS, then ovarian health and fertility are improved, but the complexity of cell preparation and modification increases
Solution Approach 1:
The patent extracts and isolates exosomes from the modified MSCs as a separate, purified therapeutic component. This extraction process simplifies the treatment preparation by removing the complex MSC structure while retaining the essential therapeutic molecules (miR144, BMP-2, TGFβ1, IL-10) in the exosome载体, making the treatment more scalable and less complex
Solution Approach 2:
The patent introduces exosomes as intermediary carriers that deliver therapeutic molecules from the modified MSCs to the target tissues. This intermediary approach separates the complex MSC production process from the actual therapeutic delivery, allowing for standardized exosome preparation while maintaining the benefits of MSC modification
Data Source
AI summary
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs. In aspects, the present disclosure provides a method of preparing MSCs, exosomes, and secretome. In aspects, the present disclosure provides a method of preventing chemotherapy-induced damage in a male mammal.